Adjusted risk of VTE by the level of serum albumin in 732 patients with available data
| Serum Albumin (g/dl) | N | Patients with VTE | Odds Ratio | 95% Confidence Interval | P Valuea |
|---|---|---|---|---|---|
| Reference range ≥3.0b | 219 | 1.00 | |||
| 2.8 to <3.0 | 66 | 3 | 1.41 | 0.34, 5.87 | 0.64 |
| 2.6 to <2.8 | 74 | 2 | 2.17 | 0.63, 7.46 | 0.22 |
| 2.4 to <2.6 | 72 | 4 | 2.05 | 0.59, 7.12 | 0.26 |
| 2.2 to <2.4 | 77 | 1 | 1.31 | 0.31, 5.62 | 0.72 |
| 2.0 to <2.2 | 82 | 8 | 4.32 | 1.46, 12.77 | 0.01 |
| <2.0 | 142 | 15 | 3.56 | 1.28, 9.88 | 0.02 |
| <2.8 versus ≥2.8 | 447/285 | 2.53 | 1.17, 5.47 | 0.02 |
↵a Logistic regression model with incremental values of serum albumin, adjusted for age at biopsy, sex, 24-hour proteinuria (g/d), immunosuppressive therapy, and registry site.
↵b Logistic regression model with serum albumin as a dichotomous variable. The serum albumin cut-point of 2.8 g/dl was determined from the incremental model (by 0.2 g/dl) reported in this table, with threshold for effect noted for values <2.8 g/dl. Adjusted for age at biopsy, sex, 24-hour proteinuria (g/d), immunosuppressive therapy, and registry site.